Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 2259

Novel malignancy associated response signatures associated with refractory tumors

Inventors: Judy Lieberman, Fabio Petrocca

Invention Types: Diagnostic/Prognostic, Therapeutics

Research Areas: Oncology/Hematology, Reproduction/Ob-Gyn

Keywords: Drug Screening, Stem/Progenitor Cell

For More Information Contact:  Dietz, Ryan

 

Invention Description:

Despite basic and clinical research directed at understanding and controlling breast cancer, breast cancer is still a major health threat worldwide. Triple-negative breast cancers (TNBC) are an especially aggressive group of tumors with the shortest survival of all breast cancer subtypes.


Dr. Lieberman's laboratory has found novel malignancy associated response signatures and assays and methods to classify and diagnose tumors, such as TNBC and other poor prognosis tumors, using a newly identified dependency gene signature associated with breast cancer malignancy (TGS). TGS expression correlates with poor survival and early onset of metastasis in breast cancer patients independent of tumor subtype. This technology is based on findings of a genome-wide siRNA lethality screen in human tumor-initiating epithelial cells, which initiate TNBC-like lesions in mice. Dr. Lieberman's laboratory identified core survival pathways and a malignancy associated response signature that are selectively associated with tumor-initiating potential that are useful for prognostic and diagnostic applications.


These efforts have uncovered new uses for drugs acting as proteasome inhibitors, Mcl-1 inhibitors, AKT inhibitors, histone deacetylase inhibitors, glycolysis inhibitors, or a combination thereof as well as novel therapeutic targets for more effective and enhanced treatment of poor prognosis tumors, such as TNBC.


These discoveries provide a platform by which companies can diagnose and treat TNBCs with novel and next generation drugs.

Applications:

• Novel malignancy associated response signatures and assays and methods thereof to classify and diagnose tumors, such as TNBC and other poor prognosis breast tumors, using a newly identified dependency gene signature identified in TNBC-initiating cells.

• New uses of drugs acting as proteasome inhibitors, Mcl-1 inhibitors, AKT inhibitors, histone deacetylase inhibitors, glycolysis inhibitors, or a combination thereof.

• New methods to screen for novel drugs for treating cancers and tumors, such as TNBC.

Competitive Advantages:

• TNBC have the shortest survival of all breast cancer subgroups.

• • TNBC rapidly acquire resistance to chemotherapy and are refractory to endocrine therapy and HER-2 inhibitors.

• This technology could diagnose deadly breast tumors early and increase the chance of a patient's survival.

• This technology could lead to new effective drugs to treat certain forms of deadly breast cancers.

Business Opportunity:

Exclusive license available and/or sponsored research

Key Publications: Paper Submitted

IPStatus: Pat. Pend.